Abstract
7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Current Topics in Medicinal Chemistry
Title: EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Volume: 11 Issue: 6
Author(s): Kristine Norregaard, Tau Benned-Jensen and Mette Marie Rosenkilde
Affiliation:
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Abstract: 7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Export Options
About this article
Cite this article as:
Norregaard Kristine, Benned-Jensen Tau and Marie Rosenkilde Mette, EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors, Current Topics in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/1568026611109060618
DOI https://dx.doi.org/10.2174/1568026611109060618 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Photosensitizer Nanoparticles for Photodynamic Therapy
Current Bioactive Compounds Suppression of Inflammatory and Allergic Responses by Pharmacologically Potent Fungus Ganoderma lucidum
Recent Patents on Inflammation & Allergy Drug Discovery HGF and RhoGTPases in Cancer Cell Motility
Current Signal Transduction Therapy Topoisomerase I and II Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry FDG-PET/CT Radiomics Models for The Early Prediction of Locoregional Recurrence in Head and Neck Cancer
Current Medical Imaging Glucan Particles Loaded with Fluorinated Emulsions: A Sensitivity Improvement for the Visualization of Phagocytic Cells by <sup>19</sup>F-MRI
Current Molecular Imaging (Discontinued) Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry An MDR-EGFP Gene Fusion Allows for Direct Cellular Localization, Function and Stability Assessment of P-Glycoprotein
Current Drug Delivery Recent Advances of p53-MDM2 Small Molecule Inhibitors (2011-Present)
Current Medicinal Chemistry Autophagy in Diabetic Retinopathy
Current Neuropharmacology Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules
Current Cancer Therapy Reviews Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Current Pharmaceutical Design Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract
Current Drug Targets